Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14049955 | 0.78 | PRMT6 (0.45) | KDM4EALDH1A1MAPTTYRADRA1D | |
| SCHEMBL10211534 | 0.73 | KDM4E (0.41) | KDM4ETDP1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL10211564 | 0.73 | MAPK1 (0.31) | MAPK1KMT2A | |
| SCHEMBL10130574 | 0.72 | KDM4E (0.43) | KDM4ETDP1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL13430014 | 0.72 | KDM4E (0.40) | KDM4ETDP1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL6641492 | 0.69 | KDM4E (0.41) | KDM4ETDP1ALDH1A1 | |
| SCHEMBL10387818 | 0.69 | KDM4E (0.41) | KDM4ETDP1ALDH1A1 | |
| SCHEMBL5147000 | 0.69 | KDM4E (0.41) | KDM4ETDP1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL223822 | 0.69 | — | — | |
| SCHEMBL3125412 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2012-02-16 | — | — | US | disclosed |
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2012-02-16 | — | — | US | disclosed |
| US-8071584-B2 | Indole carboxamides as IKK2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071584-B2 | Indole carboxamides as IKK2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
| WO-2008118724-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | KDM4E 1066/4885TDP1 2299/4885ALDH1A1 3293/4885 |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | KDM4E 1090/4885TDP1 2300/4885ALDH1A1 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.